Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jennifer L. R. Freeman"'
Autor:
Klara R. Klein, Schafer C. Boeder, Jennifer L. R. Freeman, Imogene Dunn, Chris Dvergsten, Supradeep Madduri, Erin R. Giovannetti, Carmen Valcarce, John B. Buse, Jeremy H. Pettus
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1439-1447
To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type 1 diabetes (T1D).Twenty-three participants with T1D using insulin pump therapy were randomized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18200ce2d774348839de9adf1d6d0838
https://doi.org/10.1111/dom.14697
https://doi.org/10.1111/dom.14697
Autor:
Klara R, Klein, Jennifer L R, Freeman, Imogene, Dunn, Chris, Dvergsten, M Sue, Kirkman, John B, Buse, Carmen, Valcarce, Wendy S, Lane
Publikováno v:
Diabetes Care
OBJECTIVE Despite advances in exogenous insulin therapy, many patients with type 1 diabetes do not achieve acceptable glycemic control and remain at risk for ketosis and insulin-induced hypoglycemia. We conducted a randomized controlled trial to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::059a2c4d835b6e69b6b6eed260812df7
https://doi.org/10.2337/figshare.13635230
https://doi.org/10.2337/figshare.13635230
Publikováno v:
Diabetes. 69
The Simplici-T1 trial (NCT03335371), designed to explore the safety and efficacy of TTP399 as an oral adjunctive therapy for T1DM, showed that addition of TTP399 to an optimized insulin regimen produced a statistically significant improvement in HbA1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2726a9ec454723c697c124579efc542e
https://doi.org/10.2337/db20-123-lb
https://doi.org/10.2337/db20-123-lb
Publikováno v:
Diabetes. 69
Identification of adjunctive, oral pharmacotherapies to treat type 1 diabetes (T1D) has been limited by hypoglycemia and ketoacidosis. TTP399 is a liver-selective oral glucokinase activator. In type 2 diabetes (n=190), TTP399 was shown to reduce A1C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef31edb9e8d2cee1e4ffcfe1ff567612
https://doi.org/10.2337/db20-122-lb
https://doi.org/10.2337/db20-122-lb
Publikováno v:
Diabetes. 68
TTP273, an oral, non-peptide GLP-1R agonist showed significant placebo-subtracted reductions in A1c of 0.9 and 0.7% when dosed at 150mg QPM or BID, respectively, in LOGRA, a 12-week, phase 2, double-blind, placebo-controlled randomized study [Diabete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::416b794bb8f50702579eadda7803e506
https://doi.org/10.2337/db19-1015-p
https://doi.org/10.2337/db19-1015-p
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator
Autor:
Carmen Valcarce, Kit Keller, Imogene Dunn, John B. Buse, Adrian Vella, Jennifer L. R. Freeman
The therapeutic success of interventions targeting glucokinase (GK) activation for the treatment of type 2 diabetes has been limited by hypoglycemia, steatohepatitis, and loss of efficacy over time. The clinical characteristics of patients with GK-ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf3661da4abcd2d7cc35102ff336a2b8
Autor:
Jean-Pierre Lavergne, Jean-Paul Reboud, Julie A. Pitcher, Robert J. Lefkowitz, Jennifer L. R. Freeman, Audrey Claing, Philippe Gonzalo
Publikováno v:
Biochemistry. 41:12850-12857
G protein-coupled receptor kinases are well characterized for their ability to phosphorylate and desensitize G protein-coupled receptors (GPCRs). In addition to phosphorylating the beta2-adrenergic receptor (beta2AR) and other receptors, G protein-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ecc258d99d09a4a24c13e6a86b72d84
https://doi.org/10.1021/bi020145d
https://doi.org/10.1021/bi020145d
Autor:
John J.G. Tesmer, Robert J. Lefkowitz, W. D. Capel, W.C. Stone, Jennifer L. R. Freeman, Julie A. Pitcher
Publikováno v:
Journal of Biological Chemistry. 274:34531-34534
G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation and beta-arrestin binding uncouple G protein-coupled receptors (GPCRs) from their respective G proteins and initiates the process of receptor internalization. In the case of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c07eef57c3227133b068f5107e917899
https://doi.org/10.1074/jbc.274.49.34531
https://doi.org/10.1074/jbc.274.49.34531
Autor:
Robert J. Lefkowitz, Julie A. Pitcher, Jennifer L. R. Freeman, Thomas D. Pollard, Enrique M. De La Cruz
Publikováno v:
Journal of Biological Chemistry. 273:20653-20657
G protein-coupled receptor kinases (GRKs) initiate pathways leading to the desensitization of agonist-occupied G-protein-coupled receptors (GPCRs). Here we report that the cytoskeletal protein actin binds and inhibits GRK5. Actin inhibits the kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2eebcd55a4a828fe000e1b0805b1775
https://doi.org/10.1074/jbc.273.32.20653
https://doi.org/10.1074/jbc.273.32.20653
Publikováno v:
Diabetes technologytherapeutics. 5(3)
1,5-Anhydroglucitol (1,5-AG), the 1-deoxy form of glucose, has been measured and used clinically in Japan for over a decade to monitor short-term glycemic control. Evaluation of glucose control otherwise requires measuring plasma glucose or glycated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::962020d6288e2d87338bd2b038fea602
https://pubmed.ncbi.nlm.nih.gov/12828817
https://pubmed.ncbi.nlm.nih.gov/12828817